Josefa Masa-Calles

Dr. Josefa Masa-Calles

orcid

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2014 in Eurosurveillance
Verified
Journal Article
Open access
VSV Sizaire
V Sizaire
MGM Garrido-Estepa
M Garrido-Estepa
JMJosefa Masa-Calles
Josefa Masa-Calles
MAM V Martinez de Aragon
M V Martinez de Aragon
Binary file ES_Abstracts_Final_ECDC.txt matches

18 February 2021 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
PDF file
AHAndreas Hoefer
Andreas Hoefer
DPDespina Pampaka
Despina Pampaka
SHSilvia Herrera-León
Silvia Herrera-León
SPSonia Peiró
Sonia Peiró
SVSarai Varona
Sarai Varona
LHLaura Herrera-León
Laura Herrera-León
This study examines the microbiological and epidemiological characteristics of toxigenic and nontoxigenic Corynebacterium isolates submitted to the national reference laboratory in Spain, between 2014 and 2019, in order to describe the current situation and improve our knowledge regarding these emerging pathogens. Epidemiological information was extracted from the Spanish Surveillance System.

1 December 2017 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
PDF file
MCMaría Cabrerizo
María Cabrerizo
JGJuan Pablo García-Iñiguez
Juan Pablo García-Iñiguez
FMFrancina Munell
Francina Munell
AAAlfonso Amado
Alfonso Amado
PMPaula Madurga-Revilla
Paula Madurga-Revilla
JMJosefa Masa-Calles
Josefa Masa-Calles
Enterovirus D68 was known to be the cause of mild to severe respiratory infections, but in the last few years, it has also been associated with myelitis and paralysis. This report describes the first Enterovirus D68 detections in acute flaccid paralysis cases occurring between December 2015 and March 2016 in Spain.

2 October 2021 in Viruses
Verified
Journal Article
Open access
PDF file
NLNoemí López-Perea
Noemí López-Perea
AFAurora Fernández-García
Aurora Fernández-García
JEJuan E. Echevarría
Juan E. Echevarría
FOFernando de Ory
Fernando de Ory
Mayte Perez-OlmedaMayte Perez-Olmeda
Mayte Perez-Olmeda
JMJosefa Masa-Calles
Josefa Masa-Calles
The MMR vaccination program was introduced in Spain in 1981. Consistently high vaccination coverage has led to Spain being declared free of endemic measles transmission since 2014. A few imported and import-related cases were reported during the post-elimination phase (2014 to 2020), with very low incidence: three cases per million of inhabitants a year, 70% in adults. In the post-elimination phase an increasing proportion of measles appeared in two-dose vaccinated individuals (up to 14%), posing a challenge to surveillance and laboratory investigations. Severity and clinical presentation were milder among the vaccinated. The IgM response varied and the viral load decreased, making the virus more difficult to detect. A valid set of samples (serum, urine and throat swab) is strongly recommended for accurate case classification. One third of measles in fully vaccinated people was contracted in healthcare settings, mainly in doctors and nurses, consistent with the important role of high intensity exposure in measles breakthrough cases. Surveillance protocols and laboratory algorithms should be adapted in advanced elimination settings. Reinforcing the immunity of people working in high exposure environments, such as healthcare settings, and implementing additional infection control measures, such as masking and social distancing, are becoming crucial for the global aim of measles eradication.

3 July 2001 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
JIJokin de Irala-Estévez
Jokin de Irala-Estévez
DMDiego Martínez-Concha
Diego Martínez-Concha
CDCarmen Díaz-Molina
Carmen Díaz-Molina
JMJosefa Masa-Calles
Josefa Masa-Calles
ACAmparo Serrano del Castillo
Amparo Serrano del Castillo
RNRafael Fernández-Crehuet Navajas
Rafael Fernández-Crehuet Navajas

22 November 2018 in Eurosurveillance
Verified
Journal Article
Open access
JMJosefa Masa-Calles
Josefa Masa-Calles
NTNuria Torner
Nuria Torner
NLNoemí López-Perea
Noemí López-Perea
MMMaría de Viarce Torres de Mier
María de Viarce Torres de Mier
BFBeatriz Fernández-Martínez
Beatriz Fernández-Martínez
SGSpanish AFP Surveillance Working Group
Spanish AFP Surveillance Working Group
Acute flaccid paralysis (AFP) surveillance is key for global polio eradication. It allows detecting poliovirus (PV) reintroductions from endemic countries. This study describes AFP surveillance in Spain from 1998 to 2015. During this time, 678 AFP cases were reported to the Spanish National Surveillance Network. The mean notification rate was 0.58 AFP cases/100,000 population under 15 years old (range: 0.45/100,000–0.78/100,000). Two periods (P) are described: P1 (1998–2006) with the AFP notification rate ranging from 0.66/100,000 to 0.78/100,000, peaking in 2001 (0.84/100,000); and P2 (2007–2015) when the AFP rate ranged from 0.43/100,000 to 0.57/100,000, with the lowest rate in 2009 (0.31/100,000). No poliomyelitis cases were caused by wild PV infections, although two Sabin-like PVs and one imported vaccine-derived PV-2 were detected. Overall, 23 (3.4%) cases met the hot case definition. Most cases were clinically diagnosed with Guillain–Barré syndrome (76.9%; 504/655). The adequate stool collection rate ranged from 33.3% (7/21) to 72.5% (29/40). The annual proportion of AFP cases with non-polio enterovirus findings varied widely across the study period. AFP surveillance with laboratory testing for non-polio enteroviruses must be maintained and enhanced both to monitor polio eradication and to establish sensitive surveillance for prompt detection of other enteroviruses causing serious symptoms.